ChemoCentryx (CCXI) Announces CCX140 Phase 2 Met Primary Endpoint; Wlill Present Data at ERA-EDTA Congress
Tweet Send to a Friend
ChemoCentryx (NASDAQ: CCXI) announced that data from its Phase II clinical trial in diabetic nephropathy with CCX140, an inhibitor of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
